Lukasz Wolanski

Appearances

DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL
Date
May 20, 2024
BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…
Presenter
Vipul Jairath
Western University
Speakers
GY Zou
Shashi Adsul
Jean Frederic Colombel
Icahn School of Medicine at Mount Sinai
Geert D’Haens
Marcelo Freire
Gordon Moran
Laurent Peyrin-Biroulet
William Sandborn
Shaji Sebastian
Simon Travis
Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Jurij Hanzel
Christopher Ma
Rocio Sedano
Patrick Sheridan
Naveen Arya
Melanie Beaton
Peter Bossuyt
Silvio Danese
Daniel Green
William Harlan
Marek Horynski
Jaroslaw Kierkus
Adam Kopon
Maria Klopocka
Rima Petroniene
Mark Silverberg
Lukasz Wolanski
Brian Feagan
Western University
SAFETY AND EFFICACY OF MH002, AN OPTIMIZED LIVE BIOTHERAPEUTIC PRODUCT, FOR THE TREATMENT OF MILD TO MODERATE ULCERATIVE COLITIS: A FIRST-IN-DISEASE, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL
Date
May 21, 2024
BACKGROUND: Treatment options for patients with mild to moderate ulcerative colitis (UC) failing 5ASA are limited. MH002 is an optimized consortium of 6 nonpathogenic, well characterized commensal bacteria with immunomodulating, wound healing and gut barrier protective effects…
Presenter
Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Speakers
Pieter Dewint
Margaux Vansteelant
M Peterka
David Štěpek
Jaroslaw Kierkus
Anna Wiernicka
Piotr Napora
Lukasz Wolanski
Adam Kopon
Fernando Magro
Iris Pinheiro
Sam Possemiers
Ludo Haazen
Selin Bolca